John Sorenson, MD
Ophthalmology · New York, NYNPI 1083641609
Payments from drug & device makers
Across 56 payments — averaging $32.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$531
- Regeneron Healthcare Solutions, Inc.$447
- Astellas Pharma US Inc$309
- AbbVie$181
- Genentech, Inc.$150
- Tarsus Pharmaceuticals, Inc.$66
- plus $156 from 4 others
Across 1 payment — averaging $937.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$937
What the payments were for
- Food & beverage$1,840100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 10 | $531 |
| Regeneron Healthcare Solutions, Inc. | 17 | $447 |
| Astellas Pharma US Inc | 12 | $309 |
| AbbVie | 6 | $181 |
| Genentech, Inc. | 1 | $150 |
| Tarsus Pharmaceuticals, Inc. | 3 | $66 |
| Novartis | 3 | $56 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Alimera Sciences, Inc. | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,840 in reported general payments places this provider in the 55th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TobradexTobramycin/Dexamethasone | 14 | $3,698 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $3,641 |
| Prednisolone Acetate | 58 | $3,615 |
| XalatanLatanoprost | 13 | $3,463 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,429 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $2,049 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 35 | $1,842 |
| Latanoprost | 99 | $1,161 |
| Timolol Maleate | 24 | $1,077 |
| Travoprost | 11 | $1,053 |
| Ketorolac Tromethamine | 22 | $490 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $420 |
| MoxifloxacinMoxifloxacin Hcl | 27 | $408 |
| Brimonidine Tartrate | 16 | $297 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $141 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.